Proteolysis Targeting Chimera Loaded Extracellular Vesicles for Developing Triple Negative Breast Cancer Treatment
Journal of Extracellular Vesicles · 2025-12 · 14 (12)
DOI: 10.1002/jev2.70211 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Extracellular Vesicles, online erschienen am 19.12.2025. Verfasst von Nina Erwin und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, Florida, USA. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Extracellular Vesicles. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Proteolysis targeting chimeras (PROTACs) represent an emerging targeted cancer therapy approach. However, their poor cell penetration and instability in vivo pose daunting challenges for wide‐spread clinical usage. To enhance the in vivo therapeutic efficacy of PROTACs, we introduced extracellular vesicles (EVs) for in vivo PROTAC delivery, which is leveraged by a novel microfluidic droplet‐based EV electro‐transfection system (μDES). We previously developed YX968 PROTAC, which can selectively degrade both HDAC3 and HDAC8 in triple negative breast cancer (TNBC) cells and effectively suppress the tumour cell growth without provoking global hyperacetylation. In this manuscript, we demonstrated that YX968 loaded EVs via the μDES system can retain the optimal integrity of drug loaded EVs with improved loading efficiency compared to other transfection approaches, which, in turn, significantly enhances the therapeutic function of PROTAC in vivo in TNBC mouse models. Intraperitoneal injections of YX968 loaded EVs led to significantly enhanced intratumoral degradation of HDAC3 and HDAC8 than YX986 alone, which resulted in advanced TNBC tumour inhibition without noticeable tissue toxicity. Such EV‐based delivery strategy, with a scalable EV loading approach, enhanced the in vivo PROTAC drug stability and bioavailability and improved tissue penetration and targeting, filling an important gap in the clinical translation of PROTAC‐based cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
- Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA.
- Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
- Department of Anatomy & Cell Biology, College of Medicine, University of Florida, Gainesville, Florida, USA.
- University of Florida Health Cancer Institute, University of Florida, Gainesville, Florida, USA.
ORCID-Profile: Nina Erwin, Mei He
Förderung
- NIAID NIH HHS
- NIH HHS
- NIGMS NIH HHS
- National Institutes of Health
Zitieren
APA
Erwin, N., De, U., Xiao, Y., Wang, L., Maharjan, C. K., Pan, X., Zuo, D., Awasthee, N., Zheng, G., Liao, D., Zhang, W., & He, M. (2025). Proteolysis Targeting Chimera Loaded Extracellular Vesicles for Developing Triple Negative Breast Cancer Treatment. Journal of Extracellular Vesicles, 14(12). https://doi.org/10.1002/jev2.70211
Vancouver
Erwin N, De U, Xiao Y, Wang L, Maharjan CK, Pan X, et al. Proteolysis Targeting Chimera Loaded Extracellular Vesicles for Developing Triple Negative Breast Cancer Treatment. Journal of Extracellular Vesicles. 2025;14(12). doi:10.1002/jev2.70211
BibTeX
@article{Erwin2025,
author = {Erwin, Nina and De, Umasankar and Xiao, Yufeng and Wang, Lei and Maharjan, Chandra K and Pan, Xiaoshu and Zuo, Ding and Awasthee, Nikee and Zheng, Guangrong and Liao, Daiqing and Zhang, Weizhou and He, Mei},
title = {Proteolysis Targeting Chimera Loaded Extracellular Vesicles for Developing Triple Negative Breast Cancer Treatment},
journal = {Journal of Extracellular Vesicles},
year = {2025},
volume = {14},
number = {12},
doi = {10.1002/jev2.70211}
}
EUVIMED